El Sanabary, Hoda FFouad, Manal MAbdel Razeq, Sawsan A.El Demerdash, Asmaa O.2019-12-182019-12-1820182231-3443https://doi.org/NLM ID101647669http://www.journalrepository.org/media/journals/IRJPAC_7/2018/Sep/Razeq1712018IRJPAC44345.pdfFive methods were developed for simultaneous determination of spiramycin adipate and oxytetracycline-HCl and/or tetracycline-HCl in their pharmaceutical formulations. The first one was a densitometric evaluation of thin-layer chromatograms using a mobile phase of methanol: Butanol: Chloroform: Ammonia 1% (5:1:1:1, by volume). The plates were visualized under UV lamp at 254 nm where spots appeared at Rf 0.76, 0.30 and 0.37 for spiramycin adipate, oxytetracycline-HCl and tetracycline-HCl, respectively. The chromatograms of the drugs were measured densitometrically at 240 nm for spiramycin adipate and at 350 nm for both oxytetracycline-HCl and tetracycline-HCl in the range of 0.1-0.8 µg mL-1 and 0.1-1.0 µg mL-1, respectively. Likewise, the simultaneous estimation of the cited drugs was performed by four spectrophotometric methods. Method A was a mean centering (MC) which provided spiramycin adipate determination at 232 nm t oxytetracycline-HCl or tetracyclinea third derivative (3D) through which spiramycin adipate could be estimated at 256 nm while the wavelength 281 nm was selected for oxytetracyclin C was a derivative ratio (1DR) that was established to determine spiramycin adipate only in the presence of oxytetracycline-HCl or tetracycline dual wavelength (IDW) which allowed the determination of oxytetracycline spiramycin adipate and up to 50% of its impurity tetracycline. the concentration range of 5-70 oxytetracycline-HCl and tetracycline to be in accordance with those given by reported methods. The validity of the methods was evaluated according to ICH guidelines.en-USdual wavelength.derivativemean centeringdensitometryoxytetracyclineSpiramycinArticlehttps://doi.org/NLM ID101647669